Epitome Therapeutics is a Vienna-based, next-generation epigenetic editing company spun out from EMBL in 2025. The company is developing CADENCE, a programmable platform for precise and durable activation of endogenous genes.
By engineering defined epigenetic states with multiplex capability, Epitome aims to establish calibrated gene activation as a therapeutic modality. Its initial focus is on severe liver and metabolic diseases with high unmet medical need.